News Eagle Pharmaceuticals to Present CAL02 Trial in Progress at the 2023 ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance Staff September 11, 2023 Iframe sync Post navigation Previous: New Data From an Influenza Challenge Study Further Support the Prophylactic Potential of INNA-051 to Accelerate Viral ClearanceNext: XORTX Announces Participation at Upcoming Investor Conferences More Stories Cancer Clinical Trial EHR immunotherapy News Asgard Therapeutics awarded €2.5m EIC Accelerator grant to advance lead program AT-108 toward the clinic Staff November 19, 2026 EHR Healthcare Hospitals News Pharmaceutical ALK presents new data at FAAM-EUROBAT-ISMA 2026: Data from a comparative study using adrenaline trainer devices suggests EURneffy® nasal adrenaline spray is more suitable for public places than an adrenaline auto-injector Staff November 19, 2026 Cancer DNA News AVA6207 Overcomes Topoisomerase I Inhibitor Resistance In Vitro and In Vivo with Robust and Tumor-Selective Release of Dual Exatecan and ATR Inhibitor Payloads Staff November 19, 2026